HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival.

Abstract
The fractions of tumor cells in S phase (DNA synthesis) were measured by in vitro thymidine labeling and autoradiography in 48 breast carcinomas after relapse. The S-phase fractions (SPF's), expressed as S-phase cells/100 cells, had a lognormal distribution with a geometric mean of 6.5 and a median of 7.4. Paired SPF measurements on the primary and relapsed breast carcinomas of 14 patients showed that the SPF usually increased over time. The SPF after relapse correlated negatively with the interval between primary therapy and relapse and with duration of survival after relapse. Low SPF's were associated with older age, minimal nuclear anaplasia, and estrogen receptor positivity, but SPF was the only variable that could be shown to have independent prognostic significance. Therefore, the prognostic powers of the estrogen receptor status and nuclear grade appear to result from their correlations with the SPF. Either low SPF or presence of estrogen receptor predicted response to hormonal therapy.
AuthorsJ S Meyer, J Y Lee
JournalCancer research (Cancer Res) Vol. 40 Issue 6 Pg. 1890-6 (Jun 1980) ISSN: 0008-5472 [Print] United States
PMID7371021 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Estradiol
Topics
  • Breast Neoplasms (drug therapy, pathology)
  • Cell Cycle
  • DNA Replication
  • Estradiol (metabolism)
  • Female
  • Humans
  • Interphase
  • Middle Aged
  • Neoplasm Recurrence, Local (pathology)
  • Prognosis
  • Receptors, Estrogen (metabolism)
  • Receptors, Progesterone (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: